Citius Pharmaceuticals Inc. [NASDAQ: CTXR] closed the trading session at $1.86 on 08/03/21. The day’s price range saw the stock hit a low of $1.83, while the highest price level was $1.90. The company report on July 8, 2021 that SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Citius Pharmaceuticals, Inc. – CTXR.
Pomerantz LLP is investigating claims on behalf of investors of Citius Pharmaceuticals, Inc. (“Citrus” or the “Company”) (NASDAQ: CTXR). Such investors are advised to contact Robert S. Willoughby at firstname.lastname@example.org or 888-476-6529, ext. 7980.
The investigation concerns whether Citius and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
The stocks have a year to date performance of 82.35 percent and weekly performance of -1.59 percent. The stock has been moved at 44.19 percent over the last six months. The stock has performed -13.49 percent around the most recent 30 days and changed -22.18 percent over the most recent 3-months.
If compared to the average trading volume of 9.46M shares, CTXR reached to a volume of 4280245 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Citius Pharmaceuticals Inc. [CTXR]:
The Average True Range (ATR) for Citius Pharmaceuticals Inc. is set at 0.19 The Price to Book ratio for the last quarter was 1.43, with the Price to Cash per share for the same quarter was set at 0.70.
CTXR stock trade performance evaluation
Citius Pharmaceuticals Inc. [CTXR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.59. With this latest performance, CTXR shares dropped by -13.49% in over the last four-week period, additionally plugging by 44.19% over the last 6 months – not to mention a rise of 47.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 36.10, with the RSI for the last a single of trading hit 33.46, and the three-weeks RSI is set at 39.26 for Citius Pharmaceuticals Inc. [CTXR]. The present Moving Average for the last 50 days of trading for this stock 2.5376, while it was recorded at 1.9080 for the last single week of trading, and 1.7518 for the last 200 days.
Citius Pharmaceuticals Inc. [CTXR]: An insightful look at the core fundamentals
Return on Total Capital for CTXR is now -59.46, given the latest momentum, and Return on Invested Capital for the company is -59.42. Return on Equity for this stock declined to -60.46, with Return on Assets sitting at -48.24. When it comes to the capital structure of this company, Citius Pharmaceuticals Inc. [CTXR] has a Total Debt to Total Equity ratio set at 4.02. Additionally, CTXR Total Debt to Total Capital is recorded at 3.86, with Total Debt to Total Assets ending up at 3.09. Long-Term Debt to Equity for the company is recorded at 3.03, with the Long-Term Debt to Total Capital now at 2.91.
Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.20 and a Current Ratio set at 35.20.
Citius Pharmaceuticals Inc. [CTXR]: Insider Ownership positions
There are presently around $21 million, or 12.80% of CTXR stock, in the hands of institutional investors. The top three institutional holders of CTXR stocks are: VANGUARD GROUP INC with ownership of 5,066,235, which is approximately 570.919% of the company’s market cap and around 8.50% of the total institutional ownership; BLACKROCK INC., holding 1,928,638 shares of the stock with an approximate value of $3.59 million in CTXR stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $1.84 million in CTXR stock with ownership of nearly 4548.663% of the company’s market capitalization.
Positions in Citius Pharmaceuticals Inc. stocks held by institutional investors increased at the end of September and at the time of the September reporting period, where 34 institutional holders increased their position in Citius Pharmaceuticals Inc. [NASDAQ:CTXR] by around 9,649,467 shares. Additionally, 7 investors decreased positions by around 246,121 shares, while 6 investors held positions by with 1,403,161 shares. The mentioned changes placed institutional holdings at 11,298,749 shares, according to the latest SEC report filing. CTXR stock had 22 new institutional investments in for a total of 3,236,824 shares, while 5 institutional investors sold positions of 198,721 shares during the same period.